Bioinova’s CEO and managing director MUDr Peter Bauer PhD introduces the biotech company’s shift from a university spin-off to a privately held entity. Whilst describing the powerful properties of stem cells for autologous and allogeneic transplantation, which they base their Research and Development on, Bauer evaluates the commitment that comes with Advanced Therapy Medicinal Products (ATMPs) in terms of time and costs, and shares some of his most ambitious goals as well as views on the importance of enthusiasm when it comes to leading and motivating a team.
It is important to have smart investors, willing to take a higher risk, who value factors such as know-how and Intellectual Property, and who are relatively patient regarding their investment return
